Our results regarding the high level of G-CSF in the MSC group on days 14 and 28 are contrary to the reported association of high levels of G-CSF with COVID-19 severity and the progression of inflammation in COVID-19 patients [56,57] because we did not observe any deterioration in MSC-treated patients. The gene discussed is CSF3; the disease is COVID-19.